Know Cancer

or
forgot password

Phase II Study Treatment of High Risk Non-Hodgkin's Lymphomas


Phase 2
15 Years
60 Years
Not Enrolling
Both
Lymphoma

Thank you

Trial Information

Phase II Study Treatment of High Risk Non-Hodgkin's Lymphomas


High-dose chemotherapy; untreated aggressive non-Hodgkin's lymphoma; high-risk; peripheral
blood stem cell support Patients were aged from 15 to 60 years


Inclusion Criteria:



- patients aged from 15 to 60 years

- previously untreated

- histologically proven aggressive NHL

- high aa-IPI (equal to 3)

- proper underlying organ function

Exclusion Criteria:

- transformed low-grade, lymphoblastic, mantle-cell, or Burkitt's lymphoma

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Complete response

Outcome Time Frame:

end of treatment

Safety Issue:

Yes

Principal Investigator

Noël MILPIED, MDPD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang GOELAMS

Authority:

France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Study ID:

GOELAMS 073

NCT ID:

NCT00869284

Start Date:

October 1994

Completion Date:

February 2009

Related Keywords:

  • Lymphoma
  • High-dose chemotherapy
  • aggressive NHL
  • high-risk
  • PBSC
  • Lymphoma
  • Lymphoma, Non-Hodgkin

Name

Location